Creative Medical Technology Holdings, Inc.(CELZ)Earnings, Financials & Key Ratios
CELZ•NASDAQ
$2.29
$6M mkt cap·Price updated May 7, 2026
AboutCreative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.Show more
- Revenue$6K-45.5%
- EBITDA-$6M-6.9%
- Net Income-$6M-9.1%
- EPS (Diluted)-2.52+32.1%
- Gross Margin63.43%+5.7%
- EBITDA Margin-100324.78%-95.9%
- Operating Margin-100324.78%-92.1%
- Net Margin-99916.8%-100.1%
- ROE-86.47%-31.3%
- ROIC-1258.23%-962.9%
CELZ Key Insights
Creative Medical Technology Holdings, Inc. (CELZ) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.7x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Sales declining 48.4% over 5 years
- ✗Shares diluted 61.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
CELZ Price & Volume
Creative Medical Technology Holdings, Inc. (CELZ) stock price & volume — 10-year historical chart
Loading chart...
CELZ Growth Metrics
Creative Medical Technology Holdings, Inc. (CELZ) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-48.43%
3 Years-59.24%
TTM-45.45%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-12.1%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM23.42%
Return on Capital
10 Years-61.54%
5 Years-61.54%
3 Years-66.19%
Last Year-86.82%
CELZ Peer Comparison
Creative Medical Technology Holdings, Inc. (CELZ) competitors in Regenerative Medicine and Tissue Engineering — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MESO | 1.91B | 14.80 | -17.62 | 191.39% | -5.94% | -17.1% | 0.21 | |
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 RCEL | 127.64M | 4.18 | -2.40 | 11.45% | -67.85% | |||
 VCEL | 1.79B | 35.13 | 109.78 | 16.45% | 7.35% | 6.41% | 0.28 | |
 HALO | 7.68B | 65.19 | 25.46 | 37.55% | 22.69% | 6.49% | ||
 MDXG | 548.21M | 3.69 | 11.53 | 19.99% | 7.88% | 12.86% | 0.09 | |
 OSUR | 225.25M | 3.13 | -3.33 | -38.1% | -61.93% | -15.09% | 0.04 | |
 ILMN | 21.07B | 138.71 | 25.45 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare CELZ vs Peers
Creative Medical Technology Holdings, Inc. (CELZ) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CELZ Income Statement
Creative Medical Technology Holdings, Inc. (CELZ) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 4.8K | 124.4K | 165.5K | 164.5K | 87.75K | 88.6K | 9K | 11K | 6K | 6K |
| Revenue Growth % | - | 2491.67% | 33.04% | -0.6% | -46.65% | 0.96% | -89.84% | 22.22% | -45.45% | -45.45% |
| Cost of Goods Sold | 8K | 70.38K | 45.5K | 50.6K | 47.95K | 28.49K | 3.6K | 4.4K | 2.19K | 33.14K |
| COGS % of Revenue | 166.67% | 56.57% | 27.49% | 30.76% | 54.64% | 32.16% | 40% | 40% | 36.57% | - |
| Gross Profit | -3.2K▲ 0% | 54.02K▲ 1788.3% | 120K▲ 122.1% | 113.9K▼ 5.1% | 39.8K▼ 65.1% | 60.11K▲ 51.0% | 5.4K▼ 91.0% | 6.6K▲ 22.2% | 3.81K▼ 42.3% | -27.14K▲ 0% |
| Gross Margin % | -66.67% | 43.43% | 72.51% | 69.24% | 45.36% | 67.84% | 60% | 60% | 63.43% | -452.37% |
| Gross Profit Growth % | 99.58% | 1788.28% | 122.12% | -5.08% | -65.05% | 51.01% | -91.02% | 22.22% | -42.33% | - |
| Operating Expenses | 1.17M | 1.17M | 1.25M | 1.23M | 3.17M | 10.3M | 5.63M | 5.75M | 6.02M | 6.06M |
| OpEx % of Revenue | 24470.96% | 939.11% | 755.39% | 746.95% | 3607.53% | 11630.34% | 62505.91% | 52276.92% | 100388.22% | - |
| Selling, General & Admin | 898.53K | 1.05M | 1.22M | 1.16M | 2.96M | 3.94M | 3.56M | 3.24M | 3.76M | 3.79M |
| SG&A % of Revenue | 18719.29% | 844.44% | 739.11% | 706.35% | 3378.18% | 4450.95% | 39558.99% | 29447.56% | 62724.95% | - |
| Research & Development | 260.08K | 96.62K | 0 | 0 | 109.18K | 6.27M | 1.97M | 2.4M | 2.26M | 2.18M |
| R&D % of Revenue | 5418.44% | 77.67% | - | - | 124.42% | 7075.46% | 21895.99% | 21825.25% | 37663.27% | - |
| Other Operating Expenses | 0 | 21.14K | 26.95K | 66.79K | 92.08K | 92.08K | 94.58K | 110.45K | 0 | 84.28K |
| Operating Income | -1.18M▲ 0% | -1.11M▲ 5.4% | -1.13M▼ 1.4% | -1.11M▲ 1.4% | -3.13M▼ 180.4% | -10.24M▼ 227.7% | -5.62M▲ 45.1% | -5.74M▼ 2.2% | -6.02M▼ 4.8% | -6.08M▲ 0% |
| Operating Margin % | -24537.63% | -895.68% | -682.88% | -677.71% | -3562.17% | -11562.5% | -62445.91% | -52216.92% | -100324.78% | -101379.43% |
| Operating Income Growth % | -53.75% | 5.4% | -1.43% | 1.36% | -180.4% | -227.72% | 45.14% | -2.2% | -4.8% | - |
| EBITDA | -1.16M | -1.09M | -1.1M | -1.05M | -3.03M | -10.15M | -5.53M | -5.63M | -6.02M | -5.97M |
| EBITDA Margin % | -24204.42% | -878.68% | -666.6% | -637.11% | -3457.24% | -11458.56% | -61394.98% | -51212.81% | -100324.78% | -99462.48% |
| EBITDA Growth % | -53.53% | 5.92% | -0.93% | 5% | -189.48% | -234.63% | 45.57% | -1.95% | -6.85% | -8.18% |
| D&A (Non-Cash Add-back) | 15.99K | 21.14K | 26.95K | 66.79K | 92.08K | 92.08K | 94.58K | 110.45K | 0 | 115.02K |
| EBIT | -1.18M | -12.29M | -6.59M | -35.1M | 23.49M | -10.24M | -5.62M | -5.74M | 0 | -6.1M |
| Net Interest Income | -377.59K | -1.36M | -1.9M | -1.23M | -4.28M | 100.33K | 333.56K | 250.38K | 0 | 121.36K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 100.33K | 333.56K | 250.38K | 147.81K | 121.36K |
| Interest Expense | 377.59K | 1.36M | 1.9M | 1.23M | 4.28M | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -1.48M | -12.54M | -7.35M | -35.21M | 22.34M | 100.33K | 333.56K | 250.38K | 24.48K | 121.36K |
| Pretax Income | -2.66M▲ 0% | -13.66M▼ 413.5% | -8.48M▲ 37.9% | -36.33M▼ 328.2% | 19.21M▲ 152.9% | -10.14M▼ 152.8% | -5.29M▲ 47.9% | -5.49M▼ 3.9% | -6M▼ 9.1% | -5.96M▲ 0% |
| Pretax Margin % | -55398.08% | -10977.21% | -5126.09% | -22082.21% | 21892.75% | -11449.26% | -58739.71% | -49940.74% | -99916.8% | -99356.8% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -2.66M▲ 0% | -13.66M▼ 413.5% | -8.48M▲ 37.9% | -36.33M▼ 328.2% | 19.21M▲ 152.9% | -10.14M▼ 152.8% | -5.29M▲ 47.9% | -5.49M▼ 3.9% | -6M▼ 9.1% | -5.96M▲ 0% |
| Net Margin % | -55398.08% | -10977.21% | -5126.09% | -22082.21% | 21892.75% | -11449.26% | -58739.71% | -49940.74% | -99916.8% | -99356.8% |
| Net Income Growth % | -247.11% | -413.54% | 37.87% | -328.18% | 152.89% | -152.8% | 47.88% | -3.91% | -9.13% | -12.1% |
| Net Income (Continuing) | -2.66M | -13.66M | -8.48M | -36.33M | 19.21M | -10.14M | -5.29M | -5.49M | -6M | -5.96M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10K | 0 |
| EPS (Diluted) | -17379.79▲ 0% | -11351.33▲ 34.7% | -5017.67▲ 55.8% | -626.88▲ 87.5% | 56.10▲ 108.9% | -9.28▼ 116.5% | -3.76▲ 59.5% | -3.71▲ 1.3% | -2.52▲ 32.1% | -2.31▲ 0% |
| EPS Growth % | -217.62% | 34.69% | 55.8% | 87.51% | 108.95% | -116.54% | 59.48% | 1.33% | 32.08% | 23.42% |
| EPS (Basic) | -17379.79 | -11351.33 | -5017.67 | -626.88 | 73.75 | -9.28 | -3.76 | -3.71 | -2.52 | - |
| Diluted Shares Outstanding | 153 | 1.2K | 2.07K | 57.95K | 324.86K | 1.09M | 1.41M | 1.48M | 2.38M | 2.58M |
| Basic Shares Outstanding | 153 | 1.2K | 2.07K | 57.95K | 260.5K | 1.09M | 1.41M | 1.48M | 2.38M | 2.58M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CELZ Balance Sheet
Creative Medical Technology Holdings, Inc. (CELZ) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 18.5K | 313.66K | 94.25K | 98.01K | 10.74M | 18.75M | 10.27M | 6.14M | 7.4M | 5.41M |
| Cash & Short-Term Investments | 13.7K | 304.06K | 88.65K | 98.01K | 10.72M | 18.4M | 9.99M | 5.94M | 7.21M | 5.38M |
| Cash Only | 13.7K | 304.06K | 88.65K | 98.01K | 10.72M | 8.32M | 3.47M | 5.94M | 7.21M | 5.38M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 10.08M | 6.52M | 0 | 0 | 0 |
| Accounts Receivable | 4.8K | 9.6K | 5.6K | 0 | 2.48K | 0 | 0 | 0 | 52.08K | 0 |
| Days Sales Outstanding | 365.08 | 28.17 | 12.35 | - | 10.34 | - | - | - | 3.17K | - |
| Inventory | 0 | 0 | 0 | 0 | 10.87K | 10.19K | 6.59K | 2.19K | 0 | 994 |
| Days Inventory Outstanding | - | - | - | - | 82.71 | 130.6 | 668.56 | 182 | - | 14.25 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 277.25K | 192.71K | 138.8K | 0 |
| Total Non-Current Assets | 184.65K | 163.5K | 436.56K | 619.76K | 530.96K | 438.88K | 444.29K | 533.84K | 410.51K | 441.46K |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 184.65K | 163.5K | 436.56K | 619.76K | 527.68K | 435.6K | 441.01K | 530.56K | 0 | 438.18K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 3.28K | 3.28K | 3.28K | 3.28K | 410.51K | 13.12K |
| Total Assets | 203.15K▲ 0% | 477.16K▲ 134.9% | 530.8K▲ 11.2% | 717.77K▲ 35.2% | 11.27M▲ 1469.9% | 19.19M▲ 70.3% | 10.72M▼ 44.2% | 6.67M▼ 37.8% | 7.81M▲ 17.1% | 5.85M▲ 0% |
| Asset Turnover | 0.02x | 0.26x | 0.31x | 0.23x | 0.01x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x |
| Asset Growth % | -37.01% | 134.88% | 11.24% | 35.22% | 1469.88% | 70.27% | -44.15% | -37.76% | 17.1% | -77.08% |
| Total Current Liabilities | 2.44M | 4.47M | 8.6M | 40.52M | 1.05M | 3.32M | 371.39K | 327.64K | 284.88K | 261.35K |
| Accounts Payable | 237.57K | 331.84K | 320.79K | 350.9K | 761.86K | 3.27M | 317.28K | 273.53K | 270.69K | 247.16K |
| Days Payables Outstanding | 10.84K | 1.72K | 2.57K | 2.53K | 5.8K | 41.86K | 32.17K | 22.69K | 45.03K | 2.91K |
| Short-Term Debt | 501.75K | 682.06K | 1.06M | 788.7K | 0 | 0 | 0 | 0 | 0 | 14.19K |
| Deferred Revenue (Current) | 375.89K | 10.8K | 371.37K | 639.35K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.31M | 3.24M | 6.48M | 38.58M | 0 | 0 | 0 | 0 | 284.88K | 0 |
| Current Ratio | 0.01x | 0.07x | 0.01x | 0.00x | 10.22x | 5.64x | 27.65x | 18.73x | 25.97x | 25.97x |
| Quick Ratio | 0.01x | 0.07x | 0.01x | 0.00x | 10.21x | 5.64x | 27.64x | 18.72x | 25.97x | 25.97x |
| Cash Conversion Cycle | - | - | - | - | -5.71K | - | - | - | - | -2.89K |
| Total Non-Current Liabilities | 4.13K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Debt | 915 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 2.44M | 4.47M | 8.6M | 40.52M | 1.05M | 3.32M | 371.39K | 327.64K | 284.88K | 261.35K |
| Total Debt | 513.46K | 682.06K | 1.06M | 788.7K | 0 | 0 | 0 | 0 | 0 | 14.19K |
| Net Debt | 499.77K | 378K | 973.62K | 690.69K | -10.72M | -8.32M | -3.47M | -5.94M | -7.21M | -5.36M |
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.90x |
| Interest Coverage | -3.12x | -0.82x | -0.60x | -0.91x | -0.73x | - | - | - | - | - |
| Total Equity | -2.24M▲ 0% | -3.99M▼ 78.6% | -8.07M▼ 102.1% | -39.8M▼ 393.1% | 10.22M▲ 125.7% | 15.86M▲ 55.3% | 10.34M▼ 34.8% | 6.34M▼ 38.7% | 7.52M▲ 18.7% | 5.59M▲ 0% |
| Equity Growth % | -1317.17% | -78.64% | -102.06% | -393.13% | 125.67% | 55.27% | -34.8% | -38.69% | 18.66% | -76.39% |
| Book Value per Share | -14615.51 | -3320.56 | -3903.05 | -686.90 | 31.45 | 14.51 | 7.35 | 4.28 | 3.16 | 2.17 |
| Total Shareholders' Equity | -2.24M | -3.99M | -8.07M | -39.8M | 10.22M | 15.86M | 10.34M | 6.34M | 7.51M | 5.59M |
| Common Stock | 114.8K | 902.71K | 22.49K | 768.54K | 6.34K | 1.41K | 1.43K | 1.75K | 3.14K | 2.59K |
| Retained Earnings | -3.43M | -17.08M | -25.57M | -61.89M | -43.67M | -53.81M | -59.1M | -64.59M | -70.59M | -68.7M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | -270.95K | 0 | 0 | -10K |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 10K | 0 |
CELZ Cash Flow Statement
Creative Medical Technology Holdings, Inc. (CELZ) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -889.62K | -1.05M | -1.21M | -434.56K | -2.22M | -7.8M | -8.03M | -5.3M | -5.86M | -5.86M |
| Operating CF Margin % | -18533.77% | -845.88% | -732.99% | -264.17% | -2524.99% | -8800.19% | -89198.72% | -48193.56% | -97607.42% | - |
| Operating CF Growth % | -99.81% | -18.28% | -15.28% | 64.18% | -409.9% | -251.88% | -2.96% | 33.96% | -10.47% | -77.77% |
| Net Income | -2.66M | -13.66M | -8.48M | -36.33M | 19.21M | -10.14M | -5.29M | -5.49M | -6M | -5.96M |
| Depreciation & Amortization | 15.99K | 21.14K | 26.95K | 66.79K | 92.08K | 92.08K | 94.58K | 110.45K | 121.74K | 115.02K |
| Stock-Based Compensation | 144.16K | 1.88K | 0 | 170.32K | 595.38K | 68.75K | 36.65K | 36.65K | 3.48K | 12.65K |
| Deferred Taxes | 347.56K | 11.19M | 0 | 33.98M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.1M | 1.26M | 7.18M | 979.96K | -22.36M | 0 | -34.09K | 0 | 13.34K | -16.66K |
| Working Capital Changes | 158.06K | 129.43K | 62.2K | 692.79K | 249.47K | 2.19M | -2.84M | 45.09K | 0 | -18.03K |
| Change in Receivables | -4.8K | -4.8K | 4K | 5.6K | -2.48K | 2.48K | 0 | 0 | 0 | 0 |
| Change in Inventory | 2.41M | 4.2M | 0 | 0 | -10.87K | 672 | 3.6K | 4.4K | 2.19K | 2.4K |
| Change in Payables | 171.18K | 94.76K | -11.05K | 30.11K | 410.96K | 2.51M | -2.95M | -43.85K | -2.84K | -10.08K |
| Cash from Investing | 0 | 0 | 0 | -250K | 0 | -10.08M | 3.45M | 6.32M | -50.5K | 0 |
| Capital Expenditures | 0 | 0 | 0 | -250K | 0 | 0 | -100K | -200K | 0 | 0 |
| CapEx % of Revenue | - | - | 0% | 151.98% | - | - | 1111.11% | 1818.18% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -50.5K | 0 |
| Cash from Financing | 681.45K | 1.34M | 997.68K | 693.92K | 12.84M | 15.47M | -270.95K | 1.45M | 7.17M | 4.98M |
| Debt Issued (Net) | 573.25K | 1.34M | 997.68K | 693.92K | -1.63M | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | 0 | 1000K | 1000K | -270.95K | 1000K | 0 | 1000K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -270.95K | -174.96K | 0 | -10K |
| Other Financing | 108.2K | 0 | 0 | 0 | -548.31K | 457 | 0 | 0 | 7.17M | 1.63M |
| Net Change in Cash | -208.17K▲ 0% | 290.36K▲ 239.5% | -215.41K▼ 174.2% | 9.36K▲ 104.3% | 10.63M▲ 113375.6% | -2.4M▼ 122.6% | -4.85M▼ 102.0% | 2.47M▲ 151.0% | 1.27M▼ 48.7% | -884.93K▲ 0% |
| Free Cash Flow | -889.62K▲ 0% | -1.05M▼ 18.3% | -1.21M▼ 15.3% | -684.56K▲ 43.6% | -2.22M▼ 223.7% | -7.8M▼ 251.9% | -8.13M▼ 4.2% | -5.3M▲ 34.8% | -5.86M▼ 10.5% | -5.87M▲ 0% |
| FCF Margin % | -18533.77% | -845.88% | -732.98% | -416.14% | -2524.99% | -8800.19% | -90309.83% | -48193.56% | -97607.42% | -97807.17% |
| FCF Growth % | -95.42% | -18.28% | -15.28% | 43.57% | -223.68% | -251.88% | -4.24% | 34.78% | -10.47% | -9.76% |
| FCF per Share | -5814.52 | -874.70 | -586.60 | -11.81 | -6.82 | -7.13 | -5.77 | -3.58 | -2.46 | -2.46 |
| FCF Conversion (FCF/Net Income) | 0.33x | 0.08x | 0.14x | 0.01x | -0.12x | 0.77x | 1.52x | 0.97x | 0.98x | 0.98x |
| Interest Paid | 0 | 0 | 0 | 0 | 9.19K | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CELZ Key Ratios
Creative Medical Technology Holdings, Inc. (CELZ) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | - | - | 188.02% | -77.78% | -40.34% | -65.85% | -86.47% | -88.9% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | -218.34% | -58.46% | -118.38% | -1258.23% | -1258.23% |
| Gross Margin | -66.67% | 43.43% | 72.51% | 69.24% | 45.36% | 67.84% | 60% | 60% | 63.43% | -452.37% |
| Net Margin | -55398.08% | -10977.21% | -5126.09% | -22082.21% | 21892.75% | -11449.26% | -58739.71% | -49940.74% | -99916.8% | -99356.8% |
| Debt / Equity | - | - | - | - | - | - | - | - | - | 0.00x |
| Interest Coverage | -3.12x | -0.82x | -0.60x | -0.91x | -0.73x | - | - | - | - | - |
| FCF Conversion | 0.33x | 0.08x | 0.14x | 0.01x | -0.12x | 0.77x | 1.52x | 0.97x | 0.98x | 0.98x |
| Revenue Growth | - | 2491.67% | 33.04% | -0.6% | -46.65% | 0.96% | -89.84% | 22.22% | -45.45% | -45.45% |
CELZ Frequently Asked Questions
Creative Medical Technology Holdings, Inc. (CELZ) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Creative Medical Technology Holdings, Inc. (CELZ) reported $0.0M in revenue for fiscal year 2025.
Creative Medical Technology Holdings, Inc. (CELZ) saw revenue decline by 45.5% over the past year.
Creative Medical Technology Holdings, Inc. (CELZ) reported a net loss of $6.0M for fiscal year 2025.
Dividend & Returns
Creative Medical Technology Holdings, Inc. (CELZ) has a return on equity (ROE) of -86.5%. Negative ROE indicates the company is unprofitable.
Creative Medical Technology Holdings, Inc. (CELZ) had negative free cash flow of $5.9M in fiscal year 2025, likely due to heavy capital investments.
Explore More CELZ
Creative Medical Technology Holdings, Inc. (CELZ) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates